Chaoju Eye Care Holdings Limited reported fresh on-market share repurchases through a Next Day Disclosure Return filed to the Hong Kong Stock Exchange on 1 September 2026. Key takeaways are:

• Latest repurchase activity – 1 September 2026: 111,500 ordinary shares bought back on the Stock Exchange at prices between HK$2.41 and HK$2.52, for a total consideration of HK$0.28 million (average HK$2.49 per share). – 31 August 2026: 873,500 shares were repurchased at a volume-weighted average price of HK$2.3783 per share, implying a cost of about HK$2.08 million. Both batches are pending cancellation.

• Capital structure unaffected to date – Issued share capital stood at 701.46 million shares as at both 31 August and 1 September 2026, as the above repurchased shares had not yet been cancelled at the reporting date.

• Utilisation of 2026 repurchase mandate – The current mandate, approved on 12 May 2026, allows buybacks of up to 70.52 million shares. – Cumulative repurchases since the mandate now total 4.32 million shares, equivalent to 0.61 % of the shares in issue on the mandate date.

• Compliance and future issuance restriction – The board confirmed that all purchases complied with Hong Kong Listing Rules and relevant regulations. – In line with Rule 10.06(3)(a), the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 1 October 2026.

Chaoju Eye Care’s continuing buyback programme signals ongoing execution of its authorised mandate, with the company maintaining its share count pending formal cancellation of the repurchased shares.